Crescent Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CBIO research report →
Range $36 – $36
Price Chart
About the company
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors.
- CEO
- Joshua T. Brumm
- IPO
- 2014
- Employees
- 44
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on CBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $505.64M
- P/E
- -1.84
- PEG
- -0.01
- P/S
- 33.71
- P/B
- 1.85
- EV/EBITDA
- -1.23
- Div Yield
- 0.00%
- Gross Margin
- 99.55%
- Op Margin
- -1216.61%
- Net Margin
- -1173.97%
- ROE
- -85.44%
- ROIC
- -65.94%
Latest fiscal year · YoY change
- Revenue
- $10.84M+0.0%
- Gross Profit
- $10.84M+0.0%
- Op Income
- $-152,632,000
- Net Income
- $-153,942,000-217.3%
- EPS
- $-14.78+76.6%
- OCF Growth
- -130.0%
- FCF Growth
- -364.4%
- 52W High
- $27.41
- 52W Low
- $8.72
- 50D MA
- $14.10
- 200D MA
- $16.04
- Beta
- 1.39
- RSI (14)
- 45
- Avg Volume
- 361.17K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
GlycoMimetics reported that its pivotal Phase III uproleselan study missed the overall-survival endpoint in relapsed/refractory AML, prompting a deeper data review, cash-burn reduction efforts, and an updated strategy discussion.· May 6, 2024
- Phase III uproleselan did not achieve statistical significance for overall survival in the intent-to-treat population.
- Median overall survival was 13 months with uproleselan versus 12.3 months with placebo; management said the control arm was unusually strong.
- Adverse events were described as consistent with the known chemotherapy side-effect profiles.
- Management said it will perform a full medical/statistical/regulatory review, present comprehensive data at an upcoming medical meeting, and discuss the results with the FDA.
- The company said it is rapidly evaluating ways to reduce cash burn and expects to report a revised budget in the coming weeks.
GlycoMimetics said its pivotal Phase III study of uproleselan in relapsed/refractory AML did not meet its primary endpoint of statistically significant overall survival improvement in the intent-to-treat population. The study enrolled 388 patients across 70 sites in 9 countries, and the follow-up was over 3 years. Median overall survival was 13 months for uproleselan versus 12.3 months for placebo; management called the control-arm survival unprecedented in this setting. Adverse events were consistent with known side-effect profiles of the chemotherapy backbones. Looking ahead, management expects to present a comprehensive data analysis at an upcoming medical meeting, discuss the data with the FDA, share updated plans for uproleselan as soon as reasonably possible, and report back on a revised budget in the coming weeks.
Harout Semerjian framed the quarter as a disappointing but data-rich setback, emphasizing that the company is only a few days into reviewing the results. He stressed that GlycoMimetics remains committed to understanding what the study teaches about uproleselan and the relapsed/refractory AML population, including possible subgroup signals, MRD status, transplant outcomes, and subsequent therapies. His tone was cautious and reflective, with repeated emphasis on working with medical, statistical, clinical, and regulatory experts before making decisions on the program’s next steps.
Brian Hahn did not provide a detailed financial update on the call, but management said the company is “rapidly evaluating ways to reduce our cash burn” as it completes the full analysis of the Phase III data. Harout Semerjian added that GlycoMimetics expects to report a revised budget to investors in the coming weeks. No cash balance, runway, or specific capital-allocation figures were stated in the transcript.
Analysts focused on why the study readout took longer than expected, with management saying patients lived longer than anticipated and that the strong control arm likely drove the delay. Questions also centered on whether the negative Phase III result affects the ongoing NCI trial and the Apollomics study in China; management said the NCI study is in a different line of therapy with a different backbone and endpoint, and declined to comment on Apollomics. Analysts asked about subgroup opportunities, MRD/transplant details, and whether the FDA might support a more limited filing; management said it was too early to speculate, but reiterated that it has had constructive FDA interactions and will review the full dataset before discussing any path forward.
The company still sees potential value in uproleselan because the overall dataset is rich, the study had long follow-up, and management believes there may be learnings from subgroups, MRD status, transplant rates, and therapy sequencing. GlycoMimetics also said the NCI-sponsored study is a different setting and may not have a strong read-through from this trial, leaving another potential data point ahead.
The central risk is that the pivotal Phase III trial failed to hit its primary endpoint, weakening the commercial and regulatory case for uproleselan in this indication. Management also signaled financial pressure by saying it is working to reduce cash burn and revise the budget, while the control arm’s unexpectedly strong survival raises questions about whether the drug can show meaningful benefit versus current care.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 55.7%
- Shares Outstanding
- 38.90M
- Float Shares
- 21.66M
of shares held by institutions
82 13F filers
Buy/sell ratio 0.22. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 5.90M | ▲ 1.77M |
| Fairmount Funds Management LLC | 3.60M | ▲ 853.45K |
| Bvf Inc/Il | 3.09M | ▲ 344.83K |
| Vestal Point Capital, LP | 3.00M | ▲ 1.37M |
| Blackrock, Inc. | 2.14M | ▲ 866.47K |
| Venrock Adviser, LLC | 2.13M | ▲ 158 |
| Fcpm Iii Services B.V. | 2.02M | ▲ 344.83K |
| Opaleye Management Inc. | 1.65M | ▲ 326.63K |
| Balyasny Asset Management L.P. | 1.61M | ▼ 50.96K |
| Vanguard Capital Management LLC | 1.27M | ▲ 500.88K |
| Tang Capital Management LLC | 1.16M | 0 |
| Jennison Associates LLC | 1.10M | ▲ 723.57K |
Held by 126 ETFs
Biggest fund positions in CBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | Lynch Ryan | sell | 240 |
| Sep 16, 26 | Pinkas Jan | sell | 658 |
| Sep 16, 26 | Im Ellie Eunkyung | sell | 623 |
| Sep 16, 26 | Scalzo Richard William | sell | 568 |
| Sep 16, 26 | Bispham Barbara Harlin | sell | 620 |
| Sep 16, 26 | Brumm Joshua T | sell | 1,610 |
| Sep 18, 26 | Brumm Joshua T | sell | 7,837 |
| Sep 16, 26 | McNeill Jonathan | sell | 731 |
| Sep 18, 26 | McNeill Jonathan | sell | 3,839 |
| Jul 16, 26 | Fairmount Funds Management LLC | buy | 853,450 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CBIO coverage
Recent articles, reports, and earnings notes.
No research on CBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CBIO report →Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Nov 12
Crescent Biopharma Announces Grants of Inducement Awards
globenewswire.com · Nov 3
Crescent Biopharma to Present at November Investor Conferences
globenewswire.com · Nov 2
Crescent Biopharma (NASDAQ:CBIO) Stock Rating Reaffirmed as Buy by HC Wainwright
defenseworld.net · Oct 19
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
globenewswire.com · Oct 15
Crescent Biopharma Announces Grants of Inducement Awards
globenewswire.com · Oct 6
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
globenewswire.com · Oct 5
Crescent Biopharma Announces Grants of Inducement Awards
globenewswire.com · Sep 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.